Description
AK119 is an investigational drug currently being studied in clinical trials for colorectal cancer. It is being evaluated in patients whose tumors are microsatellite stable (MSS), meaning they have specific genetic characteristics. The trials are exploring AK119 alone or in combination with another investigational drug called AK112, sometimes with or without standard chemotherapy drugs like 5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin. These trials are in early phases (Phase 1b/II) and are primarily focused on determining the safety and appropriate dosage of AK119, as well as looking for early signs of effectiveness in patients who have not responded well to standard treatments or are receiving first-line treatment. The trials are being conducted in China and involve patients with advanced colorectal cancer.
Mechanism of Action
AK119 is being investigated as a potential treatment for colorectal cancer. The specific way it works (its mechanism of action) is still being studied in clinical trials. Researchers are working to understand how it affects cancer cells and whether it can help control tumor growth, especially in MSS colorectal cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.